41677
document
Aspirin-associated iron loss as an anticancer mechanism . A consensus view has emerged favoring an anticancer effect of long-term aspirin use . Aspirin-induced loss of stored iron from chronic gastrointestinal bleeding is proposed as a mechanism underlying this beneficial effect . In iron depletion , less iron may be available for carcinogenesis through free-radical mediated mechanisms and for promotion of tumor growth . Low-dose aspirin increases gastrointestinal losses of transfused radiolabeled autologous red cells . Observational studies report lower serum ferritin values with regular aspirin use . A protective effect of induced iron reduction against cancer mortality has been confirmed in a recent trial ( FeAST ) with subjects randomized to iron reduction or observation . Serum ferritin reductions in the FeAST trial were within conventionally normal reference ranges and were quantitatively similar to ferritin reductions in observational studies in regular aspirin users . Delayed anticancer effects of aspirin are compatible with the proposed mechanism , as continual microbleeding has a gradual cumulative effect on stored iron .
41678
Intervention_Pharmacological
Aspirin-induced
41679
Intervention_Pharmacological
Low-dose aspirin
41680
Outcome_Physical
gastrointestinal losses
41681
Outcome_Physical
transfused radiolabeled autologous red cells
41682
Outcome_Physical
Serum ferritin reductions
41683
Outcome_Physical
microbleeding
41684
Participant_Condition
Aspirin-associated iron loss
41685
Participant_Condition
anticancer
41686
Participant_Condition
regular aspirin users